Core Laboratories (NYSE:CLB) Releases Q4 Earnings Guidance

Core Laboratories (NYSE:CLB) updated its fourth quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.20-0.25 for the period, compared to the consensus EPS estimate of $0.24. The company issued revenue guidance of $128.5-135.5 million, compared to the consensus revenue estimate of $134.60 million. Core Laboratories also updated its Q4 2024 guidance to 0.200-0.250 EPS.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CLB shares. Bank of America cut their target price on Core Laboratories from $16.00 to $15.00 and set an “underperform” rating for the company in a research note on Monday, July 15th. StockNews.com downgraded shares of Core Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, September 17th. Piper Sandler cut their target price on shares of Core Laboratories from $18.00 to $17.00 and set a “neutral” rating on the stock in a research note on Monday, July 15th. Finally, Stifel Nicolaus lifted their target price on Core Laboratories from $18.00 to $22.00 and gave the stock a “hold” rating in a research report on Friday, July 26th. Two equities research analysts have rated the stock with a sell rating and two have issued a hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $18.00.

Core Laboratories Stock Down 1.0 %

Shares of CLB stock traded down $0.18 on Wednesday, hitting $17.07. The company’s stock had a trading volume of 590,211 shares, compared to its average volume of 433,538. The firm’s fifty day moving average price is $18.59 and its 200-day moving average price is $18.97. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.68. Core Laboratories has a fifty-two week low of $13.82 and a fifty-two week high of $25.13. The stock has a market capitalization of $800.58 million, a price-to-earnings ratio of 19.40, a P/E/G ratio of 1.08 and a beta of 2.36.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings results on Wednesday, July 24th. The oil and gas company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. The firm had revenue of $130.58 million during the quarter, compared to analysts’ expectations of $132.85 million. Core Laboratories had a net margin of 5.44% and a return on equity of 15.20%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 earnings per share. Research analysts anticipate that Core Laboratories will post 0.8 EPS for the current year.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.